openPR Logo
Press release

Anaplastic Oligoastrocytoma Market to Witness a Pronounce Growth During 2016-2024

05-23-2018 11:42 AM CET | Health & Medicine

Press release from: Persistence Market Research pvt ltd

Anaplastic Oligoastrocytoma Market to Witness a Pronounce

Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear to be grade 4. Anaplastic oligoastrocytomas can be characterized by high cellularity, conspicuous cytologic atypism, microvascular proliferation, mitotic activity and necrosis. Patients suffering from this condition show symptoms like headache, seizure and speech or motor changes. According to the American Brain Cancer Association, clinical trials for the treatment of this tumor are in process to minimize the recurrence rate of anaplastic oligoastocytoma caused after the surgical removal of tumor or chemotherapy and radiation therapy session.

Request to Sample of Report @ https://www.persistencemarketresearch.com/samples/10502

Anaplastic oligoastrocytomas market is offers potential opportunities to cancer care industry. Factors contributing the growth of anaplastic oligoastrocytomas market are rising geriatric population, increasing incidence of anaplastic oligoastrocytomas and increasing pace of clinical trials for novel drug development. Moreover factors such as advancement in technology and innovations in diangositc techniques is expected to drive the growth of anaplastic oligoastrocytoma market over the forecast period. However, lack of specific treatment and critical diagnosis of anaplastic oligoastrocytoma is the major challenge for anaplastic oligoastrocytomas market.
Basically the treatment of anaplastic oligoastrocytoma depends on the size of the tumor. The treatment is processed by surgery to remove the tumor. In order to eliminate the cancerous cells, the combinational therapies such as chemotherapy or radiation therapy are used as effective treatment for anaplastic oligoastrocytoma.
Oligoastrocytomas is most common in adults and generally occurs at the age of 35–50. Generally these type of tumors are found in both the genders. Children of age 0-14 are often diagnosed with oligoastrocytomas and these tumors comprises of only three percent of primary brain tumors. Factors such as increasing demand for treatment therapies for anaplastic oligoastrocytoma, increasing prevalence of anaplastic oligoastrocytoma in emerging economies are expected provide traction to the growth of anaplastic oligoastrocytoma over the forecast period (2016-2026)
On the basis of region presence, anaplastic oligoastrocytoma market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The North America and Europe market are at maturity level for clinical research of treatment for anaplastic oligoastrocytomas. Markets of Asia-Pacific region have also shown keen interest in clinical trials of this tumor and are showing growth at faster pace, due to increasing incidence of anaplastic oligoastrocytoma.
Following are the companies and institutions which are involved in clinical trials of treatment for anaplastic oligoastocytomas are Tocagen, Inc., Shandong Lanjin Pharmaceuticals Co. Ltd, Keryx Biopharmaceuticals, Inc., Biogen Idec, Inc., Insys Therapeutics, Inc, Rush University Medical Center and University of California, San Diego.

Request Report for Table of Contents @ https://www.persistencemarketresearch.com/toc/10502

Report Highlights:
• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

Request to Report Methodology @ https://www.persistencemarketresearch.com/methodology/10502

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anaplastic Oligoastrocytoma Market to Witness a Pronounce Growth During 2016-2024 here

News-ID: 1059255 • Views: 132

More Releases from Persistence Market Research pvt ltd

Osteoarthritis Treatment Market Analysis By 2025 | Top Key Players are Johnson & …
Persistence Market Research (PMR) has published a new research report on the osteoarthritis treatment market titled “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” An alarming rise in the number of osteoarthritis cases is the result of a growing geriatric population worldwide. In order to cater to the needs of the rapidly increasing geriatric population as well as the female population – given that osteoarthritis prevails mostly among
Soft Tissue Repair Market Opportunity By 2024 | Top Key Players are Baxter, B. B …
Soft tissue repair is a process of replacement of destroyed or injured tissue by healthy tissue. One of the key factors driving the market is the rise in a number of accidents and accidental injuries. This is leading to the soft tissue injuries in ligaments, muscle, and tendons. Soft tissue injuries are being treated with soft tissue fixation devices and scaffolds. Increasing number of sports injuries is also driving the
Biosensor Market Forecast By 2020 | Top Key Players are Abbott Laboratories, Inc …
According to a new market report published by Persistence Market Research “Global Market Study on Biosensor: Asia-Pacific to Witness Highest Growth by 2020,” the global biosensor market was valued at USD 12,963.6 million in 2014 and is expected to grow at a CAGR of 9.7% from 2014 to 2020, to reach an estimated value of USD 22,551.2 million in 2020. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/3589 Globally, the
Growing Usage in Non-medical Sectors to Create Promising Prospects for Medical & …
Persistence Market Research has estimated the global market for medical & industrial gloves at US$ 12,868.6 Mn by the end of 2026, exhibiting robust expansion at a CAGR of 7.9% over 2018–2026. According to the latest market outlook released by the company, the global Medical & Industrial Gloves Market holds promising growth prospects over the next eight years. The market will benefit from multiple innovations through intense research and

All 5 Releases


More Releases for Anaplastic

Anaplastic Oligoastrocytoma Therapeutics Pipeline Review 2018
Anaplastic oligoastrocytoma is a type of brain tumour in which certain brain cells such as oligodendrocytes and astrocytes, rapidly increase in number and form a mass. The disease is also called mixed glioma because it involves two types of cells. Anaplastic oligoastrocytoma generally occurs in the cerebrum region. Some of the symptoms of anaplastic oligoastrocytoma include seizures, headache and change in personality. The disease can be treated by surgical methods
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Anaplastic Oligoastrocytoma Therapeutics Pipeline Analysis - Clinical Trials , R …
Anaplastic oligoastrocytoma is a type of brain tumour in which certain brain cells such as oligodendrocytes and astrocytes, rapidly increase in number and form a mass. The disease is also called mixed glioma because it involves two types of cells. Anaplastic oligoastrocytoma generally occurs in the cerebrum region. Some of the symptoms of anaplastic oligoastrocytoma include seizures, headache and change in personality. Access Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/anaplastic-oligoastrocytoma-therapeutics-pipeline-analysis
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
Anaplastic Oligoastrocytoma Market to Register Substantial Expansion by 2024
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear to
Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insights 2017
The “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of ALK drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential ALK inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,